Catechin hydrate ameliorates cerulein‑induced chronic pancreatitis via the inactivation of TGF‑β/Smad2 signaling

Kweon,Bitna; Kim,Dong-Uk; Oh,Jin-Young; Park,Sung-Joo; Bae,Gi-Sang

doi:10.3892/mmr.2023.13095

Catechin hydrate ameliorates cerulein‑induced chronic pancreatitis via the inactivation of TGF‑β/Smad2 signaling

Authors:
- Bitna Kweon
- Dong-Uk Kim
- Jin-Young Oh
- Sung-Joo Park
- Gi-Sang Bae
View Affiliations

Affiliations: Department of Pharmacology, School of Korean Medicine, Wonkwang University, Iksan, Jeollabuk 54538, Republic of Korea, Hanbang Cardio‑Renal Syndrome Research Center, School of Korean Medicine, Wonkwang University, Iksan, Jeollabuk 54538, Republic of Korea
Published online on: September 19, 2023 https://doi.org/10.3892/mmr.2023.13095
Article Number: 208
Copyright: © Kweon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic pancreatitis (CP) is a pancreatic inflammatory disease associated with histological changes, including fibrosis, acinar cell loss and immune cell infiltration, and leads to damage of the pancreas, which results in pain, weight loss and loss of pancreas function. Catechin or catechin hydrate (CH) has antioxidant, anticancer and immune‑regulatory effects. However, unlike other catechins, the antifibrotic effects of (+)‑CH have not been widely studied in many diseases, including CP. Therefore, the anti‑fibrotic effects of (+)‑CH against CP were evaluated in the present study. To assess the prophylactic effects of CH, (+)‑CH (1, 5 or 10 mg/kg) or ethanol was administered 1 h before first cerulein (50 µg/kg) injection. To assess the therapeutic effects, (+)‑CH (5 mg/kg) or ethanol was administered after cerulein injection for one or two weeks. In both methods, cerulein was injected intraperitoneally into mice once every hour, six times a day, four times a week, for a total of three weeks, to induce CP. The data showed that (+)‑CH markedly inhibited glandular destruction and inflammation during CP. Moreover, (+)‑CH prevented pancreatic stellate cell (PSC) activation and the production of extracellular matrix components, such as fibronectin 1 and collagens, which suggested that it may act as a novel therapeutic agent. Furthermore, the mechanism and effectiveness of (+)‑CH on pancreatic fibrosis were investigated in isolated PSCs. (+)‑CH suppressed the activation of Smad2 and fibrosis factors that act through transforming growth factor‑β (TGF‑β) or platelet‑derived growth factor. These findings suggest that (+)‑CH exhibits antifibrotic effects in cerulein‑induced CP by inactivating TGF‑β/Smad2 signaling.

View Figures

View References

1	Yang HY, Wang D, Liu Y, Han C, Xin L, Li ZS, Liao Z and Hu LH: Global status in chronic pancreatitis research. Pancreas. 49:1283–1289. 2020. View Article : Google Scholar : PubMed/NCBI
2	Olesen SS, Mortensen LH, Zinck E, Becker U, Drewes AM, Nøjgaard C, Novovic S, Yadav D and Tolstrup JS: Time trends in incidence and prevalence of chronic pancreatitis: A 25-year population-based nationwide study. United European Gastroenterol J. 9:82–90. 2021. View Article : Google Scholar : PubMed/NCBI
3	Etemad B and Whitcomb DC: Chronic pancreatitis: Diagnosis, classification, and new genetic developments. Gastroenterology. 120:682–707. 2001. View Article : Google Scholar : PubMed/NCBI
4	Olesen SS, Frandsen LK, Poulsen JL, Vestergaard P, Rasmussen HH and Drewes AM: The prevalence of underweight is increased in chronic pancreatitis outpatients and associates with reduced life quality. Nutrition. 43–44. 1–7. 2017.
5	Lin CH, Yeh NC, Wang JJ, Ho CH, Her SH, Tsay WI and Chien CC: Effect of chronic pancreatitis on complications and mortality in DM patients: A 10-year nationwide cohort study. J Clin Endocrinol Metab. 105:e739–e745. 2020. View Article : Google Scholar
6	Drewes AM, Krarup AL, Detlefsen S, Malmstrøm ML, Dimcevski G and Funch-Jensen P: Pain in chronic pancreatitis: The role of neuropathic pain mechanisms. Gut. 57:1616–1627. 2008. View Article : Google Scholar : PubMed/NCBI
7	Madro A: Malnutrition in chronic pancreatitis: Causes, assessment methods, and therapeutic management. Can J Gastroenterol Hepatol. 2020:88754872020.PubMed/NCBI
8	Kirkegård J, Mortensen FV and Cronin-Fenton D: Chronic pancreatitis and pancreatic cancer risk: A systematic review and meta-analysis. Am J Gastroenterol. 112:1366–1372. 2017. View Article : Google Scholar : PubMed/NCBI
9	Malka D, Hammel P, Sauvanet A, Rufat P, O'Toole D, Bardet P, Belghiti J, Bernades P, Ruszniewski P and Lévy P: Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology. 119:1324–1332. 2000. View Article : Google Scholar : PubMed/NCBI
10	Han M, Tran TPT and Oh JK: Chronic pancreatitis and cancer risk in a matched cohort study using national claims data in South Korea. Sci Rep. 12:55452022. View Article : Google Scholar : PubMed/NCBI
11	Muniraj T, Aslanian HR, Farrell J and Jamidar PA: Chronic pancreatitis, a comprehensive review and update. Part I: Epidemiology, etiology, risk factors, genetics, pathophysiology, and clinical features. Dis Mon. 60:530–550. 2014. View Article : Google Scholar : PubMed/NCBI
12	Dufour MC and Adamson MD: The epidemiology of alcohol-induced pancreatitis. Pancreas. 27:286–290. 2003. View Article : Google Scholar : PubMed/NCBI
13	Koehn FE and Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 4:206–220. 2005. View Article : Google Scholar : PubMed/NCBI
14	Chacko SM, Thambi PT, Kuttan R and Nishigaki I: Beneficial effects of green tea: A literature review. Chin Med. 5:132010. View Article : Google Scholar : PubMed/NCBI
15	Khan N and Mukhtar H: Tea polyphenols for health promotion. Life Sci. 81:519–533. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kim HK, Yang TH and Cho HY: Antifibrotic effects of green tea on in vitro and in vivo models of liver fibrosis. World J Gastroenterol. 15:5200–5205. 2009. View Article : Google Scholar : PubMed/NCBI
17	Higdon JV and Frei B: Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr. 43:89–143. 2003. View Article : Google Scholar : PubMed/NCBI
18	Isemura M: Catechin in human health and disease. Molecules. 24:5282019. View Article : Google Scholar : PubMed/NCBI
19	Asaumi H, Watanabe S, Taguchi M, Tashiro M, Nagashio Y, Nomiyama Y, Nakamura H and Otsuki M: Green tea polyphenol (−)-epigallocatechin-3-gallate inhibits ethanol-induced activation of pancreatic stellate cells. Eur J Clin Invest. 36:113–122. 2006. View Article : Google Scholar : PubMed/NCBI
20	Cao Y, Bao S, Yang W, Zhang J, Li L, Shan Z and Teng W: Epigallocatechin gallate prevents inflammation by reducing macrophage infiltration and inhibiting tumor necrosis factor-α signaling in the pancreas of rats on a high-fat diet. Nutr Res. 34:1066–1074. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wei R, Cortez Penso NE, Hackman RM, Wang Y and Mackenzie GG: Epigallocatechin-3-gallate (EGCG) suppresses pancreatic cancer cell growth, invasion, and migration partly through the inhibition of Akt pathway and epithelial-mesenchymal transition: Enhanced efficacy when combined with gemcitabine. Nutrients. 11:18562019. View Article : Google Scholar : PubMed/NCBI
22	Kim JM and Heo HJ: The roles of catechins in regulation of systemic inflammation. Food Sci Biotechnol. 31:957–970. 2022. View Article : Google Scholar : PubMed/NCBI
23	EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), . Younes M, Aggett P, Aguilar F, Crebelli R, Dusemund B, Filipič M, Frutos MJ, Galtier P, Gott D, et al: Scientific opinion on the safety of green tea catechins. EFSA J. 16:e052392018.PubMed/NCBI
24	Alshatwi AA, Hasan TN, Alqahtani AM, Syed NA, Shafi G, Al-Assaf AH and Al-Khalifa AS: Delineating the anti-cytotoxic and anti-genotoxic potentials of catechin hydrate against cadmium toxicity in human peripheral blood lymphocytes. Environ Toxicol Pharmacol. 38:653–662. 2014. View Article : Google Scholar : PubMed/NCBI
25	Babich H, Krupka M, Nissim HA and Zuckerbraun HL: Differential in vitro cytotoxicity of (−)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity. Toxicol In Vitro. 19:231–242. 2005. View Article : Google Scholar : PubMed/NCBI
26	Alshatwi AA: Catechin hydrate suppresses MCF-7 proliferation through TP53/Caspase-mediated apoptosis. J Exp Clin Cancer Res. 29:1672010. View Article : Google Scholar : PubMed/NCBI
27	Kweon B, Kim DU, Oh JY, Oh H, Kim YC, Mun YJ, Bae GS and Park SJ: Arecae pericarpium water extract alleviates chronic pancreatitis by deactivating pancreatic stellate cells. Front Pharmacol. 13:9419552022. View Article : Google Scholar : PubMed/NCBI
28	Rai A, Das S, Chamallamudi MR, Nandakumar K, Shetty R, Gill M, Sumalatha S, Devkar R, Gourishetti K and Kumar N: Evaluation of the aphrodisiac potential of a chemically characterized aqueous extract of Tamarindus indica pulp. J Ethnopharmacol. 210:118–124. 2018. View Article : Google Scholar : PubMed/NCBI
29	Shahid A, Ali R, Ali N, Hasan SK, Bernwal P, Afzal SM, Vafa A and Sultana S: Modulatory effects of catechin hydrate against genotoxicity, oxidative stress, inflammation and apoptosis induced by benzo(a)pyrene in mice. Food Chem Toxicol. 92:64–74. 2016. View Article : Google Scholar : PubMed/NCBI
30	Bragança de Moraes CM, Bitencourt S, de Mesquita FC, Mello D, de Oliveira LP, da Silva GV, Lorini V, Caberlon E, de Souza Basso B, Schmid J, et al: (+)-Catechin attenuates activation of hepatic stellate cells. Cell Biol Int. 38:526–530. 2014. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Zang G, Sandberg M, Carlsson PO, Welsh N, Jansson L and Barbu A: Activated pancreatic stellate cells can impair pancreatic islet function in mice. Ups J Med Sci. 120:169–180. 2015. View Article : Google Scholar : PubMed/NCBI
33	Steer ML, Waxman I and Freedman S: Chronic pancreatitis. N Engl J Med. 332:1482–1490. 1995. View Article : Google Scholar : PubMed/NCBI
34	Zimmermann A, Gloor B, Kappeler A, Uhl W, Friess H and Büchler MW: Pancreatic stellate cells contribute to regeneration early after acute necrotising pancreatitis in humans. Gut. 51:574–578. 2002. View Article : Google Scholar : PubMed/NCBI
35	Gress T, Menke A, Bachem M, Müller-Pillasch F, Ellenrieder V, Weidenbach H, Wagner M and Adler G: Role of extracellular matrix in pancreatic diseases. Digestion. 59:625–637. 1998. View Article : Google Scholar : PubMed/NCBI
36	Kennedy RH, Bockman DE, Uscanga L, Choux R, Grimaud JA and Sarles H: Pancreatic extracellular matrix alterations in chronic pancreatitis. Pancreas. 2:61–72. 1987. View Article : Google Scholar : PubMed/NCBI
37	Omary MB, Lugea A, Lowe AW and Pandol SJ: The pancreatic stellate cell: A star on the rise in pancreatic diseases. J Clin Invest. 117:50–59. 2007. View Article : Google Scholar : PubMed/NCBI
38	Haber PS, Keogh GW, Apte MV, Moran CS, Stewart NL, Crawford DH, Pirola RC, McCaughan GW, Ramm GA and Wilson JS: Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am J Pathol. 155:1087–1095. 1999. View Article : Google Scholar : PubMed/NCBI
39	Ohnishi H, Miyata T, Yasuda H, Satoh Y, Hanatsuka K, Kita H, Ohashi A, Tamada K, Makita N, Iiri T, et al: Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta1 regulation of pancreatic stellate cellular functions. J Biol Chem. 279:8873–8878. 2004. View Article : Google Scholar : PubMed/NCBI
40	Apte MV, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, Pirola RC and Wilson JS: Pancreatic stellate cells are activated by proinflammatory cytokines: Implications for pancreatic fibrogenesis. Gut. 44:534–541. 1999. View Article : Google Scholar : PubMed/NCBI
41	Schwarzenberg SJ and Whitcomb DC: Causes and contributing risk factors for chronic pancreatitis in children and adolescents. UpToDate in Medicine.
42	Duggan SN, Ni Chonchubhair HM, Lawal O, O'Connor DB and Conlon KC: Chronic pancreatitis: A diagnostic dilemma. World J Gastroenterol. 22:2304–2313. 2016. View Article : Google Scholar : PubMed/NCBI
43	Klöppel G and Maillet B: Pathology of acute and chronic pancreatitis. Pancreas. 8:659–670. 1993. View Article : Google Scholar : PubMed/NCBI
44	Aghdassi AA, Mayerle J, Christochowitz S, Weiss FU, Sendler M and Lerch MM: Animal models for investigating chronic pancreatitis. Fibrogenesis Tissue Repair. 4:262011. View Article : Google Scholar : PubMed/NCBI
45	Zheng L, Xue J, Jaffee EM and Habtezion A: Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 144:1230–1240. 2013. View Article : Google Scholar : PubMed/NCBI
46	Saotome T, Inoue H, Fujimiya M, Fujiyama Y and Bamba T: Morphological and immunocytochemical identification of periacinar fibroblast-like cells derived from human pancreatic acini. Pancreas. 14:373–382. 1997. View Article : Google Scholar : PubMed/NCBI
47	Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grünert A and Adler G: Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 115:421–432. 1998. View Article : Google Scholar : PubMed/NCBI
48	Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, Pirola RC and Wilson JS: Periacinar stellate shaped cells in rat pancreas: Identification, isolation, and culture. Gut. 43:128–133. 1998. View Article : Google Scholar : PubMed/NCBI
49	To WS and Midwood KS: Plasma and cellular fibronectin: Distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 4:212011. View Article : Google Scholar : PubMed/NCBI
50	Yamaguchi T, Kihara Y, Taguchi M, Nagashio Y, Tashiro M, Nakamura H and Otsuki M: Persistent destruction of the basement membrane of the pancreatic duct contributes to progressive acinar atrophy in rats with experimentally induced pancreatitis. Pancreas. 31:365–372. 2005. View Article : Google Scholar : PubMed/NCBI
51	Liu B, Ding Y, Li P, Wang T, He S, Jia Z and Yang J: MicroRNA-219c-5p regulates bladder fibrosis by targeting FN1. BMC Urol. 20:1932020. View Article : Google Scholar : PubMed/NCBI
52	Sand J, Genovese F and Karsdal M: Type IV collagen. Biochemistry of Collagens, Laminins and Elastin. Elsevier; Amsterdam: pp. 31–41. 2016, View Article : Google Scholar
53	Hu LH, Ji JT and Li ZS: Potential application of miRNAs as diagnostic and therapeutic tools in chronic pancreatitis. J Cell Mol Med. 19:2049–2057. 2015. View Article : Google Scholar : PubMed/NCBI
54	Attisano L and Wrana JL: Signal transduction by the TGF-beta superfamily. Science. 296:1646–1647. 2002. View Article : Google Scholar : PubMed/NCBI
55	Gurusamy KS, Lusuku C and Davidson BR: Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Cochrane Database Syst Rev. 2:CD0115222016.PubMed/NCBI
56	Kwon CI, Cho JH, Choi SH, Ko KH, Tirkes T, Gromski MA and Lehman GA: Recent advances in the diagnosis and management of chronic pancreatitis. Korean J Intern Med. 34:242–260. 2019. View Article : Google Scholar : PubMed/NCBI